Insmed Incorporated
Insmed Incorporated (INSM) Stock Overview
Explore Insmed Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
18.7B
P/E Ratio
-17.50
EPS (TTM)
$-5.94
ROE
-4.47%
INSM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Insmed Incorporated (INSM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $118.92.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -17.50 and a market capitalization of 18.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
William H. Lewis
1,271
700 US Highway 202/206, Bridgewater, NJ
2000